NATCO Pharma Limited

NATCOPHARM

INE987B01026

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:49 2024-06-06 am EDT			5-day change	1st Jan Change
1,034 ^INR	+1.83%		-0.72%	+27.41%

May. 28	INDIA STOCKS-Metal, pharma stocks drive Indian benchmarks higher	RE
May. 28	Transcript : NATCO Pharma Limited, Q4 2024 Earnings Call, May 28, 2024

NATCO Pharma : launches Brivaracetam tablets, in India, for treatment of epilepsy

March 01, 2021 at 09:26 am EST

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce the launch of Brivaracetam tablets under brand BRECITA in India.

Brivaracetam is indicated towards treatment of epilepsy.

Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy's under brand name Briviact. NATCO's BRECITA tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of INR 25/- and INR 35/- per tablet respectively. Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.

Contact:

Tel: +91-40-2354 7532

Web: www.natcopharma.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	DR. REDDY'S LABORATORIES LIMITED	5,897 INR	+1.27%	-1.71%	11.63B
	UCB	129.9 EUR	+0.31%	+2.12%	26.7B

Latest news about NATCO Pharma Limited

INDIA STOCKS-Metal, pharma stocks drive Indian benchmarks higher	May. 28	RE
Transcript : NATCO Pharma Limited, Q4 2024 Earnings Call, May 28, 2024	May. 28
NATCO Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 27	CI
NATCO Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 27	CI
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	May. 08	MT
Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit	Apr. 09	MT
NATCO Pharma Limited Announces Board Appointments	Mar. 27	CI
INDIA STOCKS-Indian shares erase early gains, weighed down by IT stocks	Feb. 18	RE
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024	Feb. 15	CI
Transcript : NATCO Pharma Limited, Q3 2024 Earnings Call, Feb 15, 2024	Feb. 15
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024	Feb. 14	CI
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited	Jan. 16	CI
Floods Disrupt Operations of Natco Pharma's Plant in Tamil Nadu, India	Dec. 07	MT
Transcript : NATCO Pharma Limited, Q2 2024 Earnings Call, Nov 15, 2023	Nov. 15
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend	Nov. 14	MT
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023	Nov. 14	CI
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India	Nov. 02	MT
Transcript : NATCO Pharma Limited - Shareholder/Analyst Call	23-09-29
Redcliffe Hygiene Private Limited announced that it has received INR 248 million in funding from Rainmatter, Alkemi Growth Capital LLP, NATCO Pharma Limited	23-09-11	CI
Indian Equities End Higher for Sixth Straight Day, Buoyed by Banking, Public Sector Enterprises	23-09-08	MT
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3%	23-09-08	MT

Chart NATCO Pharma Limited

Duration

Period

More charts

Company Profile

Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Companyâs segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.

Sector

Pharmaceuticals

Calendar

2024-06-10 - Investor Meeting - J M Financial

More about the company

Income Statement Evolution

More financial data

Ratings for NATCO Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,034 INR

Average target price

1,064 INR

Spread / Average Target

+2.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NATCO PHARMA LIMITED	+27.41%	2.18B
ELI LILLY AND COMPANY	+43.64%	749B
NOVO NORDISK A/S	+39.42%	605B
JOHNSON & JOHNSON	-6.58%	351B
MERCK & CO., INC.	+19.72%	328B
ABBVIE INC.	+8.78%	292B
NOVARTIS AG	+11.92%	216B
ROCHE HOLDING AG	-2.62%	214B
PFIZER, INC.	+0.03%	167B
AMGEN INC.	+6.13%	165B

Other Pharmaceuticals

NATCO Pharma Limited

Equities

NATCOPHARM

INE987B01026

Pharmaceuticals

NATCO Pharma : launches Brivaracetam tablets, in India, for treatment of epilepsy

Stocks mentioned in the article

EPS Revisions